Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline

### What you need to know What is the role of prostate-specific antigen (PSA) screening in prostate cancer? An expert panel produced these recommendations based on a linked systematic review.1 The review was triggered by a large scale, cluster randomised trial on PSA screening in men without a previous diagnosis of prostate cancer published in 2018 (box 1).2 It found no difference between one-time PSA screening and standard practice in prostate cancer mortality but found an increase in the detection of low risk prostate cancer after a median follow-up of 10 years. Box 1 ### Results of the CAP Randomized Clinical Trial2 This cluster-randomised trial of 419 582 British men was published in March 2018. After a median follow-up of 10 years, there was no significant difference in prostate cancer-specific mortality in men receiving care by general practices randomised to a single PSA screening intervention compared with men receiving care … RETURN TO TEXT

[1]  P. Dahm,et al.  Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis , 2018, British Medical Journal.

[2]  T. Agoritsas,et al.  Values and preferences of men for undergoing prostate-specific antigen screening for prostate cancer: a systematic review , 2018, BMJ Open.

[3]  Eric A. Miller,et al.  Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial , 2018, The Prostate.

[4]  Douglas K Owens,et al.  Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.

[5]  J. Brodersen,et al.  Do men with lower urinary tract symptoms have an increased risk of advanced prostate cancer? , 2018, British Medical Journal.

[6]  D. Margolis,et al.  MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis , 2018, The New England journal of medicine.

[7]  J. Sterne,et al.  Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial , 2018, JAMA.

[8]  H. D. de Koning,et al.  Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance , 2018, Cancer.

[9]  F. Hamdy,et al.  Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study , 2017, BMJ Open.

[10]  P. Dahm.  Future of screening for prostate cancer , 2017, British Medical Journal.

[11]  M. Kattan,et al.  Prostate cancer screening practices in a large, integrated health system: 2007–2014 , 2017, BJU international.

[12]  Alan D. Lopez,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study , 2017, JAMA oncology.

[13]  M. Parmar,et al.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study , 2017, The Lancet.

[14]  J. Gohagan,et al.  Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years , 2017, Cancer.

[15]  T. Tammela,et al.  Prostate Cancer and Socioeconomic Status in the Finnish Randomized Study of Screening for Prostate Cancer. , 2016, American journal of epidemiology.

[16]  P. Stattin,et al.  Family History and Probability of Prostate Cancer, Differentiated by Risk Category: A Nationwide Population-Based Study. , 2016, Journal of the National Cancer Institute.

[17]  Gordon H Guyatt,et al.  Introduction to BMJ Rapid Recommendations , 2016, British Medical Journal.

[18]  F. Hamdy,et al.  Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. , 2016, The New England journal of medicine.

[19]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[20]  R. Grobholz,et al.  A positive family history as a risk factor for prostate cancer in a population‐based study with organised prostate‐specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau) , 2016, BJU international.

[21]  H. Grönberg,et al.  A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies , 2016, Scandinavian journal of urology.

[22]  G. Mann,et al.  Men's preferences and trade‐offs for prostate cancer screening: a discrete choice experiment , 2015, Health expectations : an international journal of public participation in health care and health policy.

[23]  A. Jemal,et al.  Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. , 2015, JAMA.

[24]  Nobhojit Roy,et al.  The Global Burden of Cancer 2013. , 2015, JAMA oncology.

[25]  S. Eggener,et al.  National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Tammela,et al.  Family history in the Finnish Prostate Cancer Screening Trial , 2015, International journal of cancer.

[27]  T. Tammela,et al.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.

[28]  M. Tonelli,et al.  Recommendations on screening for prostate cancer with the prostate-specific antigen test , 2014, Canadian Medical Association Journal.

[29]  P. Carroll,et al.  Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[30]  S. Eggener,et al.  National trends in prostate cancer screening among older American men with limited 9‐year life expectancies: Evidence of an increased need for shared decision making , 2014, Cancer.

[31]  Kirsten L. Greene,et al.  Early detection of prostate cancer: AUA Guideline. , 2013, The Journal of urology.

[32]  B. Kollen,et al.  Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate‐specific antigen (PSA) testing by Dutch general practitioners , 2013, BJU international.

[33]  T. Wilt,et al.  Screening for prostate cancer. , 2013, The Cochrane database of systematic reviews.

[34]  E. Steyerberg,et al.  Men's preferences for prostate cancer screening: a discrete choice experiment , 2013, British Journal of Cancer.

[35]  J. Gohagan,et al.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.

[36]  Chris Metcalfe,et al.  Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study , 2012, BMJ : British Medical Journal.

[37]  T. Tammela,et al.  False-positive screening results in the European randomized study of screening for prostate cancer. , 2011, European journal of cancer.

[38]  Fang Fang,et al.  Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States. , 2010, Journal of the National Cancer Institute.

[39]  W. Catalona,et al.  Prostate-specific antigen screening: pro , 2010, Current opinion in urology.

[40]  H. Adami,et al.  Immediate Risk for Cardiovascular Events and Suicide Following a Prostate Cancer Diagnosis: Prospective Cohort Study , 2009, PLoS medicine.

[41]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[42]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[43]  F. Hamdy,et al.  Screening for Prostate Cancer , 2006 .

[44]  H. Ahmed,et al.  Diagnostic Accuracy of Multi-parametric MRI and TRUS Biopsy in Prostate Cancer ( PROMIS ) : A Paired Validating Confirmatory Study , 2017 .

[45]  T. Tammela,et al.  Health-related quality of life in the Finnish trial of screening for prostate cancer. , 2014, European urology.